Monthly Archives: May 2017

Getting Struck Twice: Acquisitions & Spinouts In Biotech
May 25, 2017

Lightning can definitely strike the same place twice, or so it seems in biotech. The latest example is True North Therapeutics’ recent acquisition by Bioverativ for its program addressing cold agglutinin disease, a type of rare autoimmune hemolytic anemia: it

1 Comment

Human Antibody Discovery: Of Mice And Phage
May 11, 2017

The FDA recently approved Imfinzi (durvalumab) for the treatment of bladder cancer, making it the fifth new monoclonal antibody approved this year. More than twenty antibodies have been approved by the FDA since 2015. While not quite the magic bullet envisioned

1 Comment

Doing Good To Feel Better: The Expanding Role Of Philanthropy In Drug Development
May 9, 2017

This blog was written by Ros Deegan, CBO of Bicycle Therapeutics, as part of the From The Trenches feature of LifeSciVC. As a child, I once played the fiddler in ‘Fiddler on the Roof’. I was a horrible violinist with

Leave a comment

Building A Biotech: Magenta Starts Chapter 2 With A Triple Play
May 2, 2017

This blog was written by Jason Gardner, CEO of Magenta Therapeutics and former EIR at Atlas Venture, as part of the From The Trenches feature of LifeSciVC. We are excited to open the first page of Chapter 2 at Magenta

Leave a comment